top of page
Search

Research Roundup: June 4, 2024



Best of cannabinoid science this week...


In people with multiple sclerosis, public health data from England shows an increasing trend for the number of prescriptions for Sativex (a 1:1 THC:CBD spray)

Trends in prescription and cost of Sativex, a cannabinoid-based medicine, in treating patients with multiple sclerosis in England

 

Among Canadians with inflammatory bowel disease, a survey found an increase in their cannabis use but only half would discuss it with their physicians

Cannabis Use in Patients With Inflammatory Bowel Disease Following Legalization of Cannabis in Canada

 

In a study of metabolic syndrome, a CBD/THV strip caused weight loss & a decrease in abdominal girth, systolic blood pressure & cholesterol levels

Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips

 

In an Ayurvedic medicine study of anxiety, two months of a cannabis oil lowered anxiety, improved sleep & reduced levels of stress hormones in the saliva

A pilot study to evaluate the safety and efficacy of ‘Canna Relief’ Stress Management Oil after oral consumption in patients with Stress and Mild to Moderate Anxiety Disorder


In people having breast reduction surgery, THC use did not increase complications or the need for postoperative pain killers

Tetrahydrocannabinol Use Does Not Increase Postoperative Analgesia Needs Or Complications After Breast Reduction


For exercise recovery, a review of 70 studies where CBD “demonstrated potentially beneficial properties for athlete recovery such as anti-inflammatory, neuroprotective, anxiolytic, and analgesic effects”

Prospective Analysis of Cannabidiol's Effectiveness in Post-Exercise Recovery: An integrative Systematic Review and Research Agenda

 

In people with psychosis or at ultra-high risk for psychosis, a review of 13 studies found CBD helped with positive & negative symptom improvement

Left hemisphere lateralization of the limbic system and frontoparietal network (FPN) correlates with positive and negative symptom improvement following cannabidiol (CBD) administration in psychosis and ultra-high risk (UHR) populations: A voxel-wise meta-analysis

 

For Alzheimer's disease, a review of CBD helping via the reduction of oxidative stress & neuroinflammation

Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease

 

For epilepsy, a meta-analysis of six studies on the use of CBD

The use of cannabidiol as a treatment for quantitative seizures reduction in pharmacoresistant epilepsy, a systematic review and meta-analysis

 

A review of arachidonic acid, the fatty acid used to create anandamide & one of the most ubiquitous polyunsaturated fatty acids in our systems

Arachidonic acid in aging: New roles for old players


In a mouse model of liver fibrosis, CBD improved liver function & reduced liver damage & scarring progression via the inhibition of inflammatory cytokines & the activation of PPAR-α receptors (which control genetic transcription)

Cannabidiol alleviates carbon tetrachloride-induced liver fibrosis in mice by regulating NF-κB and PPAR-α pathways

 

In a rat model of methamphetamine use disorder, CBD helped with addictive behaviors via dopamine receptors in the hippocampus (memory center of the brain)

Hippocampal D1-like dopamine receptor as a novel target for the effect of cannabidiol on extinction and reinstatement of methamphetamine-induced CPP

 

Of relevance to epilepsy, CBD directly inhibits the BK channel (voltage gated potassium channels with large amounts of potassium known as ‘Big Potassium’ (Big K)))

Direct Inhibition of BK Channels by Cannabidiol, One of the Principal Therapeutic Cannabinoids Derived from Cannabis sativa

 

For autism, a molecular docking study of how THC is beneficial for lowering inflammatory factors

Evaluation of Δ9 -tetrahydrocannabinol Effect on Autism Inflammatory Factors by Molecular Docking Study


Commentaires


bottom of page